Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H1 2016', provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) Overview 10 Therapeutics Development 11 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Stage of Development 11 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Therapy Area 12 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Indication 13 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Companies 17 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 26 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Therapeutics Assessment 28 Assessment by Monotherapy/Combination Products 28 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 35 Advenchen Laboratories, LLC 35 Amgen Inc. 36 ArQule, Inc. 37 Astellas Pharma Inc. 38 AstraZeneca Plc 39 AVEO Pharmaceuticals, Inc. 40 Batu Biologics, Inc. 41 Bayer AG 42 Boehringer Ingelheim GmbH 43 Bristol-Myers Squibb Company 44 Celon Pharma Sp. z o.o. 45 Daiichi Sankyo Company, Limited 46 Debiopharm International SA 47 Eddingpharm 48 Eisai Co., Ltd. 49 Eli Lilly and Company 51 Hutchison MediPharma Limited 52 Incyte Corporation 53 Johnson & Johnson 54 Kaken Pharmaceutical Co., Ltd. 55 Les Laboratoires Servier SAS 56 Nobelpharma Co., Ltd. 57 Novartis AG 58 Principia Biopharma Inc. 59 Vichem Chemie Research Ltd. 60 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Drug Profiles 61 ARQ-087 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 ASP-5878 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 AZD-4547 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 BAY-1163877 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 BAY-1179470 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 BAY-1187982 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 BMS-986036 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 CPL-043 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Debio-1347 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 DS-1123 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 E-7090 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 EDP-317 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 erdafitinib - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 GP-369 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 HMPL-453 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 INCB-54828 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 infigratinib - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 L-27 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 lenvatinib mesylate - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 lucitanib - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 LY-2874455 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 nintedanib - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 palifermin (recombinant) - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 PRN-1371 - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 109 Product Description 109 Mechanism Of Action 109 R&D Progress 109 Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 RPT-835 - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 S-49076 - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 trafermin - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 trafermin - Drug Profile 115 Product Description 115 Mechanism Of Action 115 R&D Progress 115 Vallovax - Drug Profile 116 Product Description 116 Mechanism Of Action 116 R&D Progress 116 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Dormant Projects 117 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Discontinued Products 119 Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Featured News & Press Releases 122 Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting 122 May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology 122 May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma 123 May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis 124 May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim's new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma 125 Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus 126 Apr 15, 2016: Debiopharm International announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective FGFR 1,2,3 inhibitor 127 Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer 128 Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer 129 Mar 03, 2016: Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm 130 Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug 130 Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations 131 Jan 27, 2016: NICE recommends nintedanib for idiopathic pulmonary fibrosis 132 Jan 26, 2016: Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease 132 Jan 18, 2016: U.S. FDA Accepts For Priority Review sNDA For Eisai'S Anticancer Agent Lenvatinib Seeking Approval For Renal Cell Carcinoma 133 Appendix 135 Methodology 135 Coverage 135 Secondary Research 135 Primary Research 135 Expert Panel Validation 135 Contact Us 135 Disclaimer 136
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Development by Companies, H1 2016 (Contd..2) 21 Products under Development by Companies, H1 2016 (Contd..3) 22 Products under Development by Companies, H1 2016 (Contd..4) 23 Products under Development by Companies, H1 2016 (Contd..5) 24 Products under Development by Companies, H1 2016 (Contd..6) 25 Number of Products under Investigation by Universities/Institutes, H1 2016 26 Products under Investigation by Universities/Institutes, H1 2016 27 Assessment by Monotherapy/Combination Products, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 32 Number of Products by Stage and Molecule Type, H1 2016 34 Pipeline by Advenchen Laboratories, LLC, H1 2016 35 Pipeline by Amgen Inc., H1 2016 36 Pipeline by ArQule, Inc., H1 2016 37 Pipeline by Astellas Pharma Inc., H1 2016 38 Pipeline by AstraZeneca Plc, H1 2016 39 Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 40 Pipeline by Batu Biologics, Inc., H1 2016 41 Pipeline by Bayer AG, H1 2016 42 Pipeline by Boehringer Ingelheim GmbH, H1 2016 43 Pipeline by Bristol-Myers Squibb Company, H1 2016 44 Pipeline by Celon Pharma Sp. z o.o., H1 2016 45 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 46 Pipeline by Debiopharm International SA, H1 2016 47 Pipeline by Eddingpharm, H1 2016 48 Pipeline by Eisai Co., Ltd., H1 2016 49 Pipeline by Eli Lilly and Company, H1 2016 51 Pipeline by Hutchison MediPharma Limited, H1 2016 52 Pipeline by Incyte Corporation, H1 2016 53 Pipeline by Johnson & Johnson, H1 2016 54 Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 55 Pipeline by Les Laboratoires Servier SAS, H1 2016 56 Pipeline by Nobelpharma Co., Ltd., H1 2016 57 Pipeline by Novartis AG, H1 2016 58 Pipeline by Principia Biopharma Inc., H1 2016 59 Pipeline by Vichem Chemie Research Ltd., H1 2016 60 Dormant Projects, H1 2016 117 Dormant Projects (Contd..1), H1 2016 118 Discontinued Products, H1 2016 119 Discontinued Products (Contd..1), H1 2016 120 Discontinued Products (Contd..2), H1 2016 121
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
